195 results
The objective of this study is to evaluate the immune respons against the H1N1 strain following vaccination with the first dose of trivalent inactivated influenza virus vaccine (Fluarix) in subjects previously vaccinated with 2 doses of H1N1…
CD8 T-cell expansions in HIV patients, treated with HAART, who have long-term suppression of HIV-RNA
To determine the nature of these expanded CD8 T-cell subsets, by performing apoptosis resistance assays and phenotypic analysis of markers that are primarily found on so-called exhausted cells.
Primary objective is to assess the safety and reactogenicity during the entire study period in subjects aged 66 years (previously enrolled in the FLU NG-036 EXT 025 Y1 study) vaccinated with the FLU NG vaccine or with Fluarix*, and in subjects aged…
To set up a cohort of HIV infected MSM who subsequently acquired HCV infection with a known date of HCV seroconversion to study:- determinants/risk factors for acquiring HCV in HIV infected MSM- the outcome of HCV treatment in this population- the…
The primary objective of this study is to demonstrate the superior antiviral efficacy of the combination of peginterferon alpha-2a plus telbivudine vs peginterferon alpha-2a monotherapy as demonstrated by HBV DNA non-detectability using the COBAS…
The primary objective of this study is to evaluate the efficacy of SCH 503034800 mg TID PO in combination with PegIntron 1.5 *g/kg QW SC plus ribavirin (800 - 1400 mg/day) in previously untreated adult chronic hepatitis C (CHC) subjects infected…
The general objective of this study is to elucidate the cellular components for HIV-1 infection in children.
The objective of this research is to identify genetic host factors influencing the clinical course and treatment of HIV infection. The identification of these genes may lead to new therapeutic or preventive approaches. In addition, the…
-
The primary objective of this trial is to compare the immunogenicity and safety (local and systemic reactions) of a reduced dose intradermal IPV (NVI) booster vaccination administered with a jet injector to a standard full dose intramuscular IPV (…
Characterization of the effects of ageing on the innate immune response against influenza.
In vitro data indicate that raltegravir is not a substrate of UGT1A4 or UGT2B7, but there is no evidence that raltegravir itself does not influence metabolism of other agents mediated by either UGT1A4 or UGT2B7.
Is the area under the curve (AUC) of the dose ribavirin once daily equal to the AUC of a half dose twice daily?
Primary objectivesImmunogenicityTo demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects…
In this pilot study patients treated with a single course of rituximab or treated with multiple courses of rituximab, matched RA controls treated with methotrexate and healthy controls will be included in order to answer the following questions:1.…
1. To investigate the etiology and incidence of respiratory tract infection in children younger than 6 years of age.2. To investigate the course of respiratory tract infections in children younger than 6 years of age.3. To investigate the clinical…
Investigate whether switch from a non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based regimen to a raltegravir-based regimen results in reduced platelet reactivity, reduced platelet-leukocyte aggregate formation…
Primary Objective: Create a complete transcriptome of blood cells from dichotomous HIV-2 infection.Secondary Objective(s): Define host factors and pathways that are implicated in the pathogenesis of HIV infection. Determine of the mechanisms that…
The primary objective of this study is:• To evaluate the efficacy of a single-tablet regimen (STR) containingelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) versus a STRcontaining elvitegravir/cobicistat/emtricitabine/…
In the current study we investigate the safety of the HBAI20 vaccine. Furthermore, the efficacy of the HBAI20 vaccine in non-responders is investigated.